Search

The article deals with the development of active ingredients that are suitable for both topical applications and dietary supplements in order to meet the growing trend of taking skincare products. Seppic, a company based in France, has developed active ingredients such as Ceramosides, a wheat lipid extract that has positive effects on skin moisture, skin elasticity, and skin wrinkles. A clinical study with 60 women also showed positive effects on hair growth and hair strength when taking ceramides from wheat lipid extract orally. Coriander seed oil has also been identified as an ingredient for reactive skin and has shown positive effects on skin redness and itching sensations. [Extracted from the article]

DermapenWorld offers a patented microneedling procedure for the treatment of alopecia. The Dermapen is used to improve the delivery and effectiveness of therapeutic agents, promote angiogenesis, release growth factors, and break down scar tissue. The procedure utilizes immune-tolerant HLA-G exosomes that activate hair growth at a cellular level and create a favorable environment for hair regrowth. These exosomes are double-lipid-enclosed structures containing proteins, nucleic acids, peptides, growth factors, and enzymes. The IT-HLA-G-EXO™ technology has anti-inflammatory properties and can reduce scalp inflammation. Various products are offered to strengthen hair follicles, renew the scalp, and improve hair growth. [Extracted from the article]

The GENTLO Microneedling RF platform of the latest generation, manufactured by HIRONIC from South Korea, has both the medical CE certification and FDA approval. It delivers excellent results for a variety of indications on the face and body, such as wrinkle treatment, skin tightening, contour improvement, skin texture improvement, scars, acne scars, inflammatory acne, pigmentation, promotion of hair growth, and mesotherapy. The treatments are comfortable and have no long downtime. By using high RF energy and long needle penetration with controlled heat release, a strong collagen neogenesis process is triggered and the texture of the skin surface is improved. The platform can be optionally equipped with other interesting handpiece technologies. The attractive purchase price leads to a quick return on investment. [Extracted from the article]

Androgenetic alopecia (AGA) affects both older men and postmenopausal women, and there is a need for effective treatment options. Studies have shown that dermal white adipose tissue (dWAT) and an inflammatory reaction play a role in the hair growth cycle. A Japanese research group has found that conditioned medium from human dental stem cells can stimulate hair growth. Different treatment options have been investigated, including the combination of platelet-rich plasma (PRP) with minoxidil, the combination of naringenin (NAR) and minoxidil, and the effect of β-nicotinamide mononucleotide (NMN) on hair growth. These studies suggest that the combination of different treatment options could be promising in promoting hair growth in AGA. [Extracted from the article]

Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The article describes the Universal MesoExpert cocktails for the treatment of androgenetic alopecia and other hair disorders. The products are manufactured in Belgium in their own laboratory and sterilized through filtration processes to avoid damaging the active ingredients in the product. The prepared solutions are passed through a special sterile membrane filter to remove microorganisms and particles. Two different MesoExpert cocktails are introduced: MESOHAIR for the prevention of hair loss and MESOHAIR PRO for the treatment of androgenetic alopecia. Both cocktails contain various ingredients such as caffeine, vitamins, and antioxidants that stimulate hair growth and improve the scalp. [Extracted from the article]

The article describes the dynamic market of scalp care and the focus on scalp health. Seppic has developed new product concepts such as Scrub & Shampoo and scalp serums to support scalp health and promote hair growth. A natural anti-dandruff conditioning complex has been developed to improve scalp condition and promote better hair growth. The market for scalp care products is growing, and consumers value scalp-specific information. [Extracted from the article]

The non-ablative fractional 1.927nm Thulium laser (LaseMD, Lutronic) is an innovative device addressing as well medical as aesthetic and cosmetic indications. The system allows nearly painfree treatments with a depth of 200µm setting multiple microbeams. The stratum corneum stays intact despite of superficial ruptures, coagulation zones appear only in the underlying layers of the skin. Thus, the Thulium laser creates perfect conditions for a laser assisted drug delivery of either cosmetic sera or medical substances like 5-ALA for daylight-PDT. Further indications for a treatment are skin rejuvenation, hair growth, actinic keratoses, hyperpigmentation and melasma. [ABSTRACT FROM AUTHOR]

Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Der Hautarzt is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Alopecia areata is a common condition that leads to nonscarring hair loss. It can be severe and lead to complete hair loss of the scalp or the whole body. In more severe cases, the disease can be very recalcitrant to treatment and result in a significant impairment of the quality of life of the patients. In recent years, there is increasing evidence on the potential of janus kinase (JAK) inhibitors to treat alopecia areata. In the beginning, this was based on case reports, but later, this potential was further established by large case series and in vitro and in vivo data. It is on this basis that JAK inhibitors are being tested specifically for the treatment of alopecia areata in phase 3, randomized, placebo-controlled trials, raising hopes that there will soon be a JAK inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of alopecia areata. Here we provide a review of the information available on the use of JAK inhibitors to treat alopecia areata, and the potential benefits and risks of this class of medications., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Background: Platelet rich plasma (PRP) injections have been reported to be an effective and low side effect treatment for androgenetic alopecia (AGA). However, robust data concerning this therapy are lacking., Aim: We address some potentially critical aspects of PRP treatment and give some reasons why study results may differ., Materials and Methods: In the following review we give a brief overview of the current literature and compare the results of the various trials., Results: In recent years, several clinical trials have been published that have revealed different but rather positive results, which offers hope to those affected by AGA and to physicians as well. However, the results were observed in methodologically weak trials and data from randomized controlled trials are lacking. Differences in trial designs have made it difficult to draw concrete conclusions about its clinical efficacy. Even in the studies where no hair-growth-promoting effect could be observed, the majority of subjects were at least satisfied with the result. The combination of several treatment approaches seems to lead to optimal improvement in hair growth., Conclusion: There are many factors that could have influenced the results of the different studies. The results were observed in methodologically weak studies, giving reason for caution when drawing conclusions. Nevertheless, the majority of the subjects were at least satisfied with the result. Given the current low level of evidence, PRP treatments need to be further investigated in larger studies., (© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

We present a case of a 46-year-old woman suffering from active inflammatory alopecia areata universalis. After frustrating use of topical and systemic glucocorticoids, cream PUVA (psoralen and ultraviolet A) therapy and dithranol in increasing dosage, the patient was treated with 2 × 5 mg per day tofacitinib per os. After about 4-6 months, hair growth commenced, which led to full regrowth of scalp hair over the 18 months of therapy, which was well tolerated. The case shows impressively that the off-label application of tofacitinib is a therapeutic option for alopecia areata.

Hair loss affects millions of people worldwide, but currently available treatment options are often dissatisfying due to side effects or limited efficacy. Pea sprout extract has been shown to improve hair density when applied topically, but its mode of action and effectiveness upon oral administration remain unknown. Our study has now shown that the application of a fluid containing 2% pea sprout extract on a defined scalp zone of 10 volunteers enhances the expression of defined genes relevant for hair, namely fibroblast growth factor-7 (FGF7) and noggin, by 56 and 85%, respectively. Additionally, a subsequent pilot nutrition intervention study in 21 volunteers proved that pea sprout extract is also effective when consumed as dietary supplement. The daily intake of 100 mg pea sprout extract (AnaGain™ Nu) for 8 weeks significantly reduced hair loss already after 28 days of treatment (p < 0.002). No adverse events were reported. Consequently, pea sprout extract may be an effective means to safely promote hair growth and reduce hair loss in individuals experiencing excessive hair shedding., (© 2019 The Authors. Phytotherapy Research published by John Wiley & Sons Ltd.)